Get the Stockscreener App
1.40
5.41%
-0.08
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Forecast
The Barinthus Biotherapeutics Plc Adr (BRNS) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $0.9688, representing a -30.80% decrease from the current price of $1.40. The highest analyst price target is $1.5304, and the lowest is $0.4072.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month BRNS Price Target
Average 1.1169
(-20.22% Downside)
Is Barinthus Biotherapeutics Plc Adr (BRNS) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 51.81 | Neutral |
| STOCH(9,6) | 19.04 | Buy |
| STOCHRSI(14) | 4.2378 | Buy |
| MACD(12,26) | 0.1391 | Sell |
| ADX(14) | 44.79 | Buy |
| William %R | -79.17 | Neutral |
| CCI(14) | -40.13 | Neutral |
Buy: 3
Sell: 1
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
1.6625
Sell
|
1.5168
Sell
|
| MA20 |
1.4073
Sell
|
1.4231
Sell
|
| MA50 |
1.1184
Buy
|
1.2131
Buy
|
| MA100 |
1.0049
Buy
|
1.1094
Buy
|
| MA200 |
1.0511
Buy
|
1.1811
Buy
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, BRNS could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 5 signaling Sell signals and 3 Neutral signals. This might be a good time to open fresh positions on BRNS, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 51.81 indicates that BRNS is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 19.04 indicates that BRNS is oversold. This indicates that BRNS price is at or near the lowest level over a specified lookback period.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 4.2378 indicates that BRNS is oversold. This suggests that BRNS price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 44.79 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -40.13 indicates that BRNS is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term BRNS price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Barinthus Biotherapeutics Plc Adr financial reports and earnings history, Barinthus Biotherapeutics Plc Adr (BRNS) stock could reach $3.7977 by 2030, $17.82 by 2040 and $27.50 by 2050. See the projected annual prices until 2050 of the Barinthus Biotherapeutics Plc Adr stock below:
- Barinthus Biotherapeutics Plc Adr (BRNS) is expected to reach an average price of $10.16 in 2035, with a high prediction of $10.58 and a low estimate of $10.04. This indicates an $625.70% rise from the last recorded price of $1.40.
- Barinthus Biotherapeutics Plc Adr (BRNS) stock is projected to chart a bullish course in 2040, with an average price target of $17.52, representing an $1,152% surge from its current level. The forecast ranges from a conservative $17.57 to a sky-high $17.82.
- Our analysts predict Barinthus Biotherapeutics Plc Adr (BRNS) to jump 1,851% by 2045, soaring from $19.74 to an average price of $27.32, potentially reaching $26.82. While $19.74 is the low estimate, the potential upside is significant.
- Barinthus Biotherapeutics Plc Adr (BRNS) stock is expected to climb by 2050, reaching an average of $26.97, a $1,827% jump from its current level. However, a wide range of estimates exists, with high and low targets of $27.50 and $27.38, respectively, highlighting the market's uncertainty.
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Year by Year Forecast
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2025
Barinthus Biotherapeutics Plc Adr Stock (BRNS) is expected to reach an average price of $1.4438 in 2025, with a high prediction of $2.8753 and a low estimate of $0.0123. This indicates an +3.13% rise from the last recorded price of $1.40.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| September, 2025 | $0.7071 | $0.4072 | $1.5304 | -49.49% |
| October, 2025 | $0.6085 | $0.3262 | $0.7974 | -56.54% |
| November, 2025 | $0.4822 | $0.4376 | $1.1844 | -65.56% |
| December, 2025 | $0.6289 | $0.1998 | $2.2335 | -55.08% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2026
The predicted value for Barinthus Biotherapeutics Plc Adr (BRNS) in 2026 is set at an average of $0.796. Estimates vary from a peak of $1.5916 to a trough of $0.000394, indicating an -43.14% surge from the present price of $1.40.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $0.26 | $0.0166 | $1.1098 | -81.43% |
| February, 2026 | $0.0113 | $0.1413 | $0.0706 | -99.20% |
| March, 2026 | $0.6475 | $0.000394 | $0.6775 | -53.75% |
| April, 2026 | $0.1441 | $0.0534 | $0.7772 | -89.71% |
| May, 2026 | $0.0853 | $0.2044 | $0.1047 | -93.91% |
| June, 2026 | $0.182 | $0.0556 | $0.5128 | -87.00% |
| July, 2026 | $0.00185 | $0.00185 | $1.5916 | -99.87% |
| August, 2026 | $1.08 | $0.0785 | $0.2898 | -22.86% |
| September, 2026 | $0.8765 | $0.9316 | $0.8758 | -37.40% |
| October, 2026 | $0.246 | $0.246 | $0.3774 | -82.43% |
| November, 2026 | $0.8676 | $0.5689 | $0.6496 | -38.03% |
| December, 2026 | $0.6021 | $0.7421 | $0.8134 | -57.00% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Barinthus Biotherapeutics Plc Adr (BRNS) is $1.3517, with a high forecast of $2.4861 and a low forecast of $0.2173. This indicates an -3.45% decrease from the last price of $1.40.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $0.7037 | $0.5349 | $0.6837 | -49.73% |
| February, 2027 | $0.6252 | $0.2173 | $0.9497 | -55.34% |
| March, 2027 | $2.1255 | $0.6981 | $1.6255 | +51.82% |
| April, 2027 | $1.6594 | $1.7219 | $1.6809 | +18.53% |
| May, 2027 | $0.9992 | $0.9992 | $1.1528 | -28.63% |
| June, 2027 | $1.6166 | $1.3147 | $1.4236 | +15.47% |
| July, 2027 | $1.2885 | $1.4285 | $1.5221 | -7.97% |
| August, 2027 | $1.3604 | $1.2139 | $1.3404 | -2.83% |
| September, 2027 | $1.2177 | $0.8518 | $1.4258 | -13.02% |
| October, 2027 | $2.938 | $1.5986 | $2.438 | +109.86% |
| November, 2027 | $2.4422 | $2.5122 | $2.4861 | +74.45% |
| December, 2027 | $1.8605 | $1.7524 | $1.9283 | +32.89% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2028
In 2028, Barinthus Biotherapeutics Plc Adr (BRNS) is projected to reach an average price of $2.7913, with a high projection of $4.0964 and a low estimate of $1.4862. This indicates an +99.38% rise from the last price of $1.40.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $2.3327 | $2.2685 | $2.1397 | +66.62% |
| February, 2028 | $1.9749 | $2.1149 | $2.2307 | +41.06% |
| March, 2028 | $2.1651 | $1.8929 | $2.0751 | +54.65% |
| April, 2028 | $1.8373 | $1.4862 | $1.6773 | +31.24% |
| May, 2028 | $3.4913 | $2.2034 | $3.2913 | +149.38% |
| June, 2028 | $2.9438 | $3.3025 | $3.2119 | +110.27% |
| July, 2028 | $2.6063 | $2.5056 | $2.4544 | +86.16% |
| August, 2028 | $3.1094 | $3.0069 | $2.9394 | +122.10% |
| September, 2028 | $2.4819 | $2.5719 | $2.87 | +77.28% |
| October, 2028 | $2.8144 | $2.8726 | $2.7244 | +101.03% |
| November, 2028 | $2.8476 | $2.1207 | $2.3076 | +103.40% |
| December, 2028 | $4.2964 | $2.8082 | $4.0964 | +206.89% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2029
The 2029 price forecast for Barinthus Biotherapeutics Plc Adr Stock (BRNS) is $3.8283 on average, with a high prediction of $4.9016 and a low estimate of $2.7551. This represents an +173.45% increase from the previous price of $1.40.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $3.6024 | $3.8406 | $4.0096 | +157.32% |
| February, 2029 | $3.4453 | $3.2588 | $3.2753 | +146.09% |
| March, 2029 | $3.8181 | $3.7849 | $3.6481 | +172.72% |
| April, 2029 | $3.1609 | $3.2509 | $3.5713 | +125.78% |
| May, 2029 | $2.4769 | $3.4069 | $3.3737 | +76.92% |
| June, 2029 | $3.4597 | $2.7551 | $2.9197 | +147.12% |
| July, 2029 | $5.1016 | $3.413 | $4.9016 | +264.40% |
| August, 2029 | $4.3705 | $4.6087 | $4.8074 | +212.18% |
| September, 2029 | $4.1836 | $4.0121 | $4.0136 | +198.83% |
| October, 2029 | $4.5025 | $4.501 | $4.3568 | +221.61% |
| November, 2029 | $4.1157 | $3.9299 | $4.1183 | +193.98% |
| December, 2029 | $3.1188 | $4.0488 | $4.023 | +122.77% |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Price Forecast for 2030
Barinthus Biotherapeutics Plc Adr Stock (BRNS) is expected to reach an average price of $4.9507 in 2030, with a high forecast of $6.5119 and a low forecast of $3.3896. This signifies an +253.62% surge from the last price of $1.40.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $3.5937 | $3.3896 | $3.7977 | +156.69% |
| February, 2030 | $5.9202 | $6.0251 | $5.7067 | +322.87% |
| March, 2030 | $5.1385 | $5.3767 | $5.506 | +267.04% |
| April, 2030 | $4.922 | $4.7653 | $4.752 | +251.57% |
| May, 2030 | $5.2038 | $5.2171 | $5.0654 | +271.70% |
| June, 2030 | $4.7872 | $4.6089 | $4.8122 | +241.95% |
| July, 2030 | $3.8391 | $4.0241 | $4.6723 | +174.22% |
| August, 2030 | $4.395 | $4.3874 | $4.4025 | +213.93% |
| September, 2030 | $6.7179 | $6.8228 | $6.5119 | +379.85% |
| October, 2030 | $5.4375 | $5.9055 | $6.2964 | +288.39% |
| November, 2030 | $5.8714 | $5.5185 | $5.6413 | +319.38% |
| December, 2030 | $5.905 | $5.9332 | $5.7741 | +321.79% |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):